Chronic Kidney Diseases Clinical Trial
Official title:
"Kidney Health: Eat Well, Live Well": A Program to Reduce Kidney Injury and Early CKD Progression Through Nutrition & Empathetic Support From a Health Partner
Verified date | December 2023 |
Source | University of Texas at Austin |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This two-arm, parallel randomized trial study will assess the efficacy of a 6-month (26 weeks) community-based program in reducing kidney injury (as Urine Albumin to Creatinine ratio, uACR), cardiovascular risk (as Hemoglobin A1C and blood pressure), mental health (as PHQ-8) and diet quality (as fruits and vegetables intake and Healthy Eating Index) in community-dwelling, low-income adults diagnosed with early chronic kidney disease (stages 2 or 3 and not on kidney replacement therapies) compared to educational materials and usual care alone.
Status | Enrolling by invitation |
Enrollment | 330 |
Est. completion date | May 2025 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult (18 years of age or older) - Primary care visit at either one of the three partner clinics from Harris Health [Smith Clinic, Harris Health Outpatient Center (located on the LBJ campus), or Martin Luther King Jr. Health Center (MLK)] and a primary care patient within Harris Health System - Have had at least 1 visit in the past 18 months with prior history in the clinic (i.e., not first visit) - Diagnosis of CKD (Stage 2, 3a, and 3b) as defined by estimated Glomerular Filtration Rate (eGFR) = 30 and <90 mL/min/1.73 m2 OR CDK 1 or undiagnosed with urine Albumin Creatinine Ratio = 30 mg/g - Within the past 12 months, the most current serum K+ = 4.6 mEq/L - English or Spanish speaking - Ability to participate in the program at least 6 months - Ability to clean, prepare, refrigerate/freeze food products that are given to them - Have access to receive SMS text messages - Location of preferred produce bag delivery within an available delivery zone Exclusion Criteria: - CKD 4, ESRD or on dialysis. - Taking certain medications chronically (more than twice a week for 90 days) that may interfere with K+ metabolism (such as non-steroidal anti-inflammatory drugs (NSAIDs), as self-reported during enrollment screening - Taking mineralocorticoid receptor antagonists - Taking Warfarin - Diagnosis of any specific kidney conditions (such as polycystic kidney disease, glomerulonephritis, Lupus associated with Nephritis, Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)) that would contraindicate study participation as determined by physician - Medical history of organ transplant that would contraindicate study participation as determined by physician - Received immunotherapy for primary or secondary kidney disease within 6 months prior to enrolment - Diagnostic of heart failure conditions Class IV in the New York Heart Association (NYHA) functional classification - Had myocardial infarction, unstable angina, stroke, or transient ischemic attack (TIA) within 12 weeks prior to enrolment - Had coronary revascularization (PCI, CABG) or valvular repair within 12 weeks prior to enrolment - On active hospice care as self-reported during enrollment screening - Diagnosis of active malignancy requiring treatment that would contraindicate study participation as determined by physician - Has decompensated cirrhosis as determined by physician - Cognitive impairment that would contraindicate study participation as self-reported during enrollment screening |
Country | Name | City | State |
---|---|---|---|
United States | Harris Health System's Martin Luther King Jr. Health Center | Houston | Texas |
United States | Harris Health System's Outpatient Center | Houston | Texas |
United States | Harris Health System's Smith Clinic | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas at Austin | Harris Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Social engagement as measured by the Lubben Social Network scale 6-item | Self-administered. The LSNS-6 is a self-report measure of social engagement with family and friends. The sum of the all items yields a total score that ranges between 0 and 30, with a higher score indicating more social engagement. | Baseline, 6 months | |
Other | Perception of kidney disease and role of diet as measured by the Brief Illness Perception Questionnaire | Self-administered. Answers are on a 0-10 sliding scale, except for one open-ended ranking question. Increases in item scores represent linear increases in the dimension measured.
It contains 9 questions addressing the individual's cognitive perceptions, control over illness, beliefs about the effectiveness of treatment, experience of symptoms and emotional aspects. To better tailor it to the study population, "illness" was replaced by "kidney problem". And one question about perceived impact of food on disease was added to tailor it to the intervention. |
Baseline, 6 months | |
Other | General health and quality of life as measured by scores on the MOS Short-form 12-item (SF-12) | Self-administered. Measures physical and mental health status. Summary scores range from 0-100, with higher scores indicating a better self-reported level of health. | Baseline, 6 months | |
Other | Food security status as assessed by the USDA Food Security Survey Module: Six-Item Short Form | Self-administered. Self-report assessment of access to food in the past 30 days. The sum of affirmative responses to the six questions in the module yields the household's raw score on the scale. Scores can range from 0 to 6, with higher scores indicating lower food security. | Baseline, 6 months | |
Other | Estimated Glomerular Filtration Rate (eGFR) | Obtained from Electronic Health Records. Any lab result available from 18 months prior to and 15 month post enrollment date will be obtained for study participants. | As available 18 months before enrollment in the study and 15 months after study participation ends | |
Other | Changes in diet quality as estimates of individual mean dietary intake and frequency of dairy consumption | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Food group of dairy is reported as cup equivalents/day. | Baseline, 3 months, 6 months | |
Other | Changes in diet quality as estimates of individual mean dietary intake of added sugars | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Reported added sugars as teaspoon equivalents/day. | Baseline, 3 months, 6 months | |
Other | Changes in diet quality as estimates of individual mean dietary intake and frequency of whole grains | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Reported whole grains as ounce equivalents/day. | Baseline, 3 months, 6 months | |
Other | Changes in diet quality as estimates of individual mean dietary intake of fiber | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Reported fiber as g/day. | Baseline, 3 months, 6 months | |
Other | Changes in diet quality as estimates of individual mean dietary intake of calcium | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Reported calcium as mg/day. | Baseline, 3 months, 6 months | |
Other | Changes in diet quality as frequency of red and processed meat consumption | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. And reported red meat and processed meat as frequencies (times per day). | Baseline, 3 months, 6 months | |
Other | Changes in frequency and intake of eggs | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Added for its acid-inducing properties in chronic kidney disease. Reported as frequencies only (times per day) and amount. | Baseline, 3 months, 6 months | |
Other | Changes in frequency and intake of chicken/turkey | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Added for its acid-inducing properties in chronic kidney disease. Reported as frequencies only (times per day). | Baseline, 3 months, 6 months | |
Other | Changes in frequency and intake of fish | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Added for its association with reduced CVD risk. Reported as frequencies only (times per day). | Baseline, 3 months, 6 months | |
Other | Changes in type of cheese consumption when reported | Changes in diet quality will be measured by obtaining individual mean dietary intake, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Soft vs. hard cheese types added for the acid-inducing properties of hard cheese in chronic kidney disease. Reported as type associated with dairy consumption. | Baseline, 3 months, 6 months | |
Primary | Urine albumin:creatinine ratio (UACR) | Marker of kidney damage and a useful predictor of cardiovascular (CV) events in adults. Uses spot urine to estimate 24-hour urine albumin excretion. UACR > 30 mg/g indicates kidney damage. | Baseline, 3 months, 6 months | |
Secondary | Hemoglobin A1C | Finger stick point-of-care portable device. Measures the average blood sugar levels over the past 3 months with a result in %. Higher A1C levels indicate poorer glycemic control and higher risk of diabetes complications. | Baseline, 3 months, 6 months | |
Secondary | Blood pressure (systolic/diastolic) | Direct measurement with automatic blood pressure cuff. | Baseline, 3 months, 6 months | |
Secondary | Food intake in the past 30 days as assessed by the Dietary Screener Questionnaire from NHANES 2009-10 | 30-day food frequency questionnaire (screener) that asks for frequency of intake in the past month (per month, per week, or per day) of 28 items such as cereal, red meat, fruits and vegetables.
This study includes four food items linked to kidney health (and mostly acid-inducing): eggs, chicken/turkey, fish, and cheese. Questions are asked in the same fashion as the other questions in the tool. |
Baseline, 3 months, 6 months | |
Secondary | Changes in diet quality as estimates of individual mean dietary intake and frequency of fruits and vegetables consumption | Changes in diet quality will be measured by obtaining individual mean dietary intake from the Dietary Screener Questionnaire, as well as frequency of food group consumption, as per analytical instructions in the National Cancer Institute, using USDA nutrient database. Reported per fruits and vegetables as cup equivalents/day. | Baseline, 3 months, 6 months | |
Secondary | Anxiety as measured by scores on the Generalized Anxiety Disorder 7-item (GAD-7) | Self-administered. Based on some of the DSM-V criteria for General Anxiety Disorder to identify probable cases of GAD along with measuring anxiety symptom severity. Responders are asked to rate the frequency of anxiety symptoms in the last 2 weeks on a Likert scale ranging from 0 (not at all) to 3 (nearly every day). Items are summed to provide a total score (0-21) to inform severity (1-4 minimal symptoms; 5-9 mild symptoms; 10-14 moderate symptoms; 15-21 severe symptoms). | Baseline, 3 months, 6 months | |
Secondary | Depressive symptoms as measured by scores on the Patient Health Questionnaire 8-item (PHQ-8) | Self-administered. Based on the nine DSM-V criteria listed under criterion A for Major Depressive Disorder. Responders are asked to rate the frequency of depression symptoms in the last 2 weeks on a Likert scale ranging from 0 (not at all) to 3 (Nearly every day). The sum of responses to each item yields a total score that screens for depression and its severity: not depressed (0-2), mild (3-5), moderate (6-8), and severe (9-12). | Baseline, 3 months, 6 months | |
Secondary | Loneliness measured by scores on the 3-item UCLA Loneliness Scale | Self-administered. Respondents rate each item as 'Never' , 'Rarely', 'Sometimes' or 'Often'. Scores range from 3 to 9. Higher numbers imply greater loneliness. | Baseline, 3 months, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06386172 -
Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm
|
N/A | |
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT03434145 -
Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases
|
N/A | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Terminated |
NCT05022329 -
COVID-19 Vaccine Boosters in Patients With CKD
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
Recruiting |
NCT04961164 -
Resistant Starch Prebiotic Effects in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05015647 -
Low Protein Diet in CKD Patients at Risk of Malnutrition
|
N/A | |
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Recruiting |
NCT06094231 -
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT04831021 -
Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role?
|
N/A | |
Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
Recruiting |
NCT04422652 -
Combination of Novel Therapies for CKD Comorbid Depression
|
Phase 2 | |
Completed |
NCT05055362 -
Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
|
N/A | |
Not yet recruiting |
NCT06330480 -
Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT03176862 -
Left Ventricular Fibrosis in Chronic Kidney Disease
|
N/A | |
Terminated |
NCT02539680 -
Intestinal Phosphate Transporter Expression in CKD Patients
|
N/A |